| Literature DB >> 35223201 |
Zhi Xian Kong1, Rina N Karunakaran1, Kartini Abdul Jabar1, Sasheela Ponnampalavanar2, Chun Wie Chong3, Cindy Shuan Ju Teh1.
Abstract
BACKGROUND: Carbapenem resistant Enterobacteriaceae (CRE) has rapidly disseminated worldwide and has become a global threat to the healthcare system due to its resistance towards "last line" antibiotics. This study aimed to investigate the prevalence of CRE and the resistance mechanism as well as the risk factors associated with in-hospital mortality.Entities:
Keywords: Carbapenem resistant Enterobacteriaceae; Carbapenemase; Epidemiology; Porins; Pulse-field gel electrophoresis
Year: 2022 PMID: 35223201 PMCID: PMC8877335 DOI: 10.7717/peerj.12830
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Comparison between CRE samples type, identified CRE species and carbapenemase genes detected in 2014 and 2015.
| 2014 ( | 2015 ( | |
|---|---|---|
|
| ||
| Blood | 5 | 30 |
| Urine | 8 | 21 |
| Tracheal secretion | 5 | 17 |
| Sputum | 2 | 13 |
| Bronchoalveolar fluid | 3 | 4 |
| Pleural fluid | 1 | 0 |
| Pus | 1 | 0 |
| Nasopharyngeal secretion | 1 | 2 |
| Respiratory secretion | 0 | 1 |
| Swab | 0 | 5 |
| Peritoneal fluid swab | 1 | 3 |
| Peritoneal slough swab | 1 | 0 |
| Bone swab | 0 | 2 |
| Backbone suction swab | 0 | 2 |
| Cerebrospinal fluid swab | 0 | 1 |
| Bile swab | 0 | 1 |
| Abdomen fluid swab | 0 | 1 |
| Cyst swab | 0 | 1 |
| Fluid swab | 0 | 1 |
| Sacral swab | 1 | 2 |
| Groin swab | 1 | 1 |
| Stoma swab | 1 | 0 |
| Tissue swab | 0 | 6 |
| Wound swab | 2 | 7 |
| Breast swab | 0 | 1 |
| Pus swab | 0 | 5 |
| Ear swab | 0 | 1 |
| Rectal swab | 1 | 1 |
| Tip swab | 0 | 0 |
| Pigtail aspirate swab | 0 | 1 |
| Chest tube swab | 0 | 1 |
| Catheter swab | 0 | 1 |
| Latex A fluid swab | 0 | 1 |
| Eye swab | 0 | 1 |
|
| ||
|
| 25 | 115 |
|
| 1 | 11 |
|
| 4 | 2 |
|
| 0 | 2 |
|
| 2 | 2 |
|
| 0 | 1 |
|
| 2 | 0 |
|
| 0 | 1 |
|
| ||
| 19 | 53 | |
| 11 | 103 | |
| 0 | 3 | |
| 0 | 1 | |
| 0 | 0 | |
| 0 | 0 | |
| No targeted genes detected | 5 | 13 |
|
| ||
|
| 3 | 3 |
|
| 3 | 5 |
|
| 6 | 15 |
The demographic and clinical data of patients associated with in-hospital all-cause mortality.
| Variables | Survivors ( | Non-survivors (56) | |
|---|---|---|---|
|
| 54.21 ± 21.99 | 56.02 ± 20.67 | 0.610b |
|
| |||
|
| 28 | 19 | 0.903 |
|
| 32 | 20 | 0.816 |
|
| 19 | 14 | 0.716 |
|
| 6 | 3 | 1.000a |
|
| |||
|
| 60 | 31 | 0.064 |
|
| 25 | 25 | 0.064 |
|
| 44.98 ± 31.75 | 35.34 ± 28.45 | 0.035b |
|
| |||
|
| 25 | 21 | 0.316 |
|
| 32 | 28 | 0.147 |
|
| 11 | 21 | 0.000 |
|
| 13 | 12 | 0.501 |
|
| 3 | 3 | 1.000a |
|
| 7 | 4 | 1.000a |
|
| 11 | 4 | 0.275 |
|
| 4 | 0 | 0.152a |
|
| 8 | 4 | 0.763a |
|
| 3 | 3 | 0.682a |
|
| 9 | 3 | 0.363a |
|
| 5 | 2 | 0.703a |
|
| 8 | 5 | 0.923 |
|
| 3 | 0 | 0.277a |
|
| 4 | 7 | 0.114a |
|
| 4 | 6 | 0.195a |
|
| 5 | 5 | 0.518a |
|
| 2 | 1 | 0.518a |
|
| 1 | 0 | 1.000a |
|
| 1 | 0 | 1.000a |
|
| 34 | 28 | 0.242 |
|
| 1 | 1 | 1.000a |
|
| 0 | 1 | 0.397a |
|
| 0 | 1 | 0.397a |
|
| 5 | 0 | 0.157a |
|
| 81 (95.3%) | 56 (100%) | 0.152a |
|
| 50 (58.8%) | 37 (66.1%) | 0.479a |
|
| |||
|
| 52 (61.2%) | 14 (25.0%) | 0.000 |
|
| 33 (38.8%) | 42 (75.0%) | 0.000 |
|
| 0.048 | ||
|
| 15 | 10 | |
|
| 18 | 32 | |
|
| |||
|
| 38 (44.7%) | 24 (42.9%) | 0.829 |
|
| 16 (18.8%) | 11 (19.6%) | 0.904 |
|
| 1 (1.2%) | 1 (1.8%) | 1.000a |
|
| 18 (21.2%) | 16 (28.6%) | 0.315 |
|
| 12 (14.1%) | 4 (7.1%) | 0.201 |
Note:
P were obtained using chi-square test unless stated otherwise. P-valuesa was obtained using Fishers’ exact test. P-valuesb was obtained using Mann Whitney U test.
Sensitivity to imipenem, meropenem and colistin among CRE strains.
| Sensitive (≤1 µg/mL) ( | Intermediate (2 µg/mL) ( | Resistant (≥4 µg/mL) ( | |
|---|---|---|---|
|
| |||
|
| 25 | 19 | 96 |
|
| 2 | 5 | 5 |
|
| 2 | 2 | 2 |
|
| 0 | 0 | 2 |
|
| 1 | 1 | 2 |
|
| 0 | 0 | 1 |
|
| 0 | 0 | 0 |
|
| 0 | 1 | 1 |
|
| 0 | 0 | 1 |
|
| |||
|
| 30 | 18 | 92 |
|
| 7 | 1 | 4 |
|
| 2 | 1 | 3 |
|
| 1 | 0 | 1 |
|
| 2 | 1 | 1 |
|
| 0 | 0 | 1 |
|
| 1 | 0 | 1 |
|
| 0 | 1 | 0 |
|
|
| ||
|
| |||
|
| 130 | 10 | |
|
| 12 | 0 | |
|
| 6 | 0 | |
|
| 1 | 1 | |
|
| 4 | 0 | |
|
| 1 | 0 | |
|
| 2 | 0 | |
|
| 1 | 0 |
Figure 1The occurrence of pulsotype XbaI4 among CRKp strains from 2014 to 2015.
Sporadic isolation of pulsotype XbaI4 was observed in the first two quarters of 2014. However, there was a steep increment in the isolation of this pulsotype from Q4 2014 to Q1 2015. A gradual decrement in the isolation of pulsotype XbaI4 has been observed from Q2 of 2015.